LUMAKRAS Drug Patent Profile

When do Lumakras patents expire, and when can generic versions of Lumakras launch?

Lumakras is a drug marketed by Amgen Inc and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and eighty-six patent family members in thirty-nine countries.

The generic ingredient in LUMAKRAS is sotorasib. One supplier is listed for this compound. Additional details are available on the sotorasib profile page.

DrugPatentWatch^® Generic Entry Outlook for Lumakras

Lumakras was eligible for patent challenges on May 28, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 21, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for LUMAKRAS

International Patents:	186
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	60
Clinical Trials:	5
Patent Applications:	1,058
Drug Prices:	Drug price information for LUMAKRAS
What excipients (inactive ingredients) are in LUMAKRAS?	LUMAKRAS excipients list
DailyMed Link:	LUMAKRAS at DailyMed

See drug prices for LUMAKRAS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LUMAKRAS

Constraining patent/regulatory exclusivity:

10,519,146

NDA:

214665

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUMAKRAS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
China Medical University Hospital	PHASE1
National Cancer Institute (NCI)	Phase 2
Vitrac Therapeutics, LLC	Phase 1

See all LUMAKRAS clinical trials

US Patents and Regulatory Information for LUMAKRAS

LUMAKRAS is protected by ten US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,519,146.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-002	Jan 20, 2023		RX	Yes	Yes
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-003	Jun 26, 2024		RX	Yes	No
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-002	Jan 20, 2023		RX	Yes	Yes	12,280,056
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-002	Jan 20, 2023		RX	Yes	Yes	11,426,404

EU/EMA Drug Approvals for LUMAKRAS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Amgen Europe BV	Lumykras	sotorasib	EMEA/H/C/005522Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.	Authorised	no	no	no	2022-01-06

International Patents for LUMAKRAS

When does loss-of-exclusivity occur for LUMAKRAS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LUMAKRAS around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	111882
Argentina	122783
Argentina	122784
Argentina	122785

LUMAKRAS (sotorasib) Market Dynamics and Financial Trajectory: Launch Timeline, Pricing, Growth Drivers, and IP/Generic Risk

Last updated: July 22, 2026

LUMAKRAS (sotorasib) has moved from early, biomarker-enriched uptake toward a more structurally constrained market as competitors expand and as treatment sequencing evolves in KRAS G12C–mutant metastatic non-small cell lung cancer (mNSCLC) and beyond. Financially, the drug’s trajectory has been driven by (1) conversion of test-identified patients into treated patients, (2) label and regimen expansion across tumor types, and (3) durability of benefit versus chemotherapy and competing KRAS G12C inhibitors. Near-term revenue visibility is tied to ongoing adoption in second-line and later settings, trial-readout risk from next-generation KRAS G12C strategies, and the timing of biosimilar or generic-like substitution is not relevant because LUMAKRAS is a small molecule with patent exclusivity and Orange Book–listed coverage that delays generic entry.

---

How has LUMAKRAS (sotorasib) performed financially since launch?

Featured snippet answer: LUMAKRAS has grown from launch-era sales driven by rapid penetration in KRAS G12C–mutant mNSCLC into a broader oncology share, but growth is increasingly sensitive to trial outcomes and competitive dynamics as KRAS G12C rival drugs and earlier-line strategies expand.

Revenue curve characteristics that have mattered

Adoption mechanics: uptake is limited by biomarker testing rates and local turnaround. Financial performance correlates with:

• percent of eligible patients with confirmed KRAS G12C status
• payer acceptance and formulary placement
• physician comfort with toxicity profiles and monitoring
• alignment with guideline positioning after pivotal outcomes

Sequencing and line-of-therapy: revenue momentum typically strengthens when LUMAKRAS is:

• positioned as a preferred option after progression on immunotherapy and platinum chemotherapy
• supported by durable response narratives versus chemotherapy
• included in broader treatment pathways outside lung cancer

Competitive pressure: the market share rate depends on whether next-generation or alternative KRAS G12C agents are perceived as:

• better tolerated
• more efficacious in key subgroups (brain metastases, high PD-L1, prior lines)
• more synergistic in combination regimens that become standard

What to watch on quarterly reads

Because LUMAKRAS is used in oncology with a biomarker gate:

• watch sales elasticity to testing and reimbursement (new starts proxy)
• watch patient persistence (refill and ongoing treatment effects are less “one-and-done” than many acute therapies)
• watch geographic mix because payer coverage varies by market

---

What drives LUMAKRAS market dynamics in KRAS G12C–mutant mNSCLC?

Featured snippet answer: Market dynamics in mNSCLC hinge on biomarker prevalence, line-of-therapy adoption, and competition from other KRAS G12C inhibitors and combination regimens that change standard of care.

Epidemiology and addressable population

KRAS G12C mutation is a defined molecular subset of NSCLC. Commercial opportunity scales with:

• KRAS G12C prevalence in tested patient panels
• proportion progressing into labeled lines
• survival and treatment duration affecting the “active patient” base

Clinical positioning and how it impacts sales velocity

Sales velocity increases when LUMAKRAS:

• demonstrates clear benefit versus the sequencing baseline in real-world cohorts
• carries a tolerability profile that supports long-cycle therapy
• is incorporated into practical workflows at major institutions

When competitors move to earlier lines or show superiority in specific populations, LUMAKRAS growth slows even if absolute patient numbers remain stable.

Payer and guideline effects

In oncology:

• formulary tiers and prior authorization requirements can delay initial conversion
• guideline inclusion drives adoption, especially in community settings
• specialty pharmacy distribution patterns can smooth or disrupt monthly starts

---

Which competitors pressure LUMAKRAS, and how does that change its financial trajectory?

Featured snippet answer: Competitors pressure LUMAKRAS through differential efficacy, tolerability, combination utility, and earlier-line adoption, which can cap growth even when the total KRAS G12C market expands.

Competitive map by mechanism and class adjacency

For KRAS G12C:

• other KRAS G12C inhibitors compete for the same biomarker-positive population
• combination approaches can shift preference away from monotherapy

How competition changes unit economics

Revenue can grow slower due to:

• faster formulary switching as clinicians gain experience
• higher uptake of competitor agents that show better response in key subgroups
• reduced persistence if patients switch after progression

Net effect on financial trajectory

The typical pattern for an oncology targeted agent after initial penetration:

1. strong early share capture
2. plateau when label/line-of-therapy breadth stabilizes
3. decline or slower growth when competitor data changes sequencing

---

What is LUMAKRAS pricing and payer behavior, and what does it imply for sales?

Featured snippet answer: For high-cost targeted oncology drugs, payer behavior and net price pressure can matter as much as patient uptake for the financial trajectory, especially as competition increases.

What influences net price

• discounting under payer contracts
• performance-based arrangements where present
• patient assistance and copay dynamics at high co-pay tiers
• contract duration and renegotiation cycles after competitive launches

What matters for business planning

• net price trajectory can weaken even with stable patient counts
• market share can be maintained but revenue may decline due to price compression
• payer coverage can widen when evidence consolidates, reducing friction for patient starts

---

How sensitive is LUMAKRAS revenue to biomarker testing and treatment sequencing?

Featured snippet answer: LUMAKRAS revenue is structurally sensitive to KRAS G12C testing coverage and to whether it remains favored in later lines or shifts backward as competitors move forward.

Biomarker testing sensitivity

Sales depend on:

• testing rates for KRAS G12C
• lab capacity and turnaround times
• sample adequacy and tissue vs liquid biopsy adoption
• real-world confirmation of mutation status before therapy starts

Sequencing sensitivity

Revenue risk increases if:

• a competing therapy demonstrates benefit in earlier lines and becomes preferred
• treatment guidelines incorporate alternative regimens that reduce monotherapy share
• combination regimens become standard and new agents capture partner value

---

What is LUMAKRAS’s IP and exclusivity coverage outlook affecting generic entry risk?

Featured snippet answer: LUMAKRAS is protected by a patent estate listed in the U.S. patent system and by regulatory exclusivity periods; meaningful generic risk is constrained by Orange Book–listed patents and patent litigation/expiration timing rather than by near-term regulatory exclusivity for a drug-like pathway.

How generic risk is assessed for LUMAKRAS

For small molecules like sotorasib:

• track Orange Book listed patents (drug substance, drug product, formulations, and methods)
• map patent expiry dates to anticipated FDA approval eligibility windows
• monitor patent litigation (including Paragraph IV challenges if filed)

Why this matters for market dynamics

Even without generic competitors currently:

• the market often anticipates future entry and begins shifting formularies
• analysts model the revenue cliff based on the earliest date of legal generic entry
• settlements can move the effective launch date

---

What formulations, methods of use, and other patents can block LUMAKRAS substitutes?

Featured snippet answer: Patent coverage typically includes composition-of-matter for the active ingredient plus additional coverage for formulations and specific therapeutic uses, which can delay generic development even if the drug substance remains out of scope.

Patent estate structure businesses typically model

• composition-of-matter patents (core protection)
• formulation patents (dosage form, stability, particle properties)
• method-of-use patents (line of therapy, KRAS G12C–mutant populations)
• combination or treatment-monitoring method claims

Business impact

• formulators must design around formulation claims
• method-of-use claims can limit how generic labels align with FDA-approved indications
• carve-outs in settlements can create “at-risk” launch zones

---

What is the Orange Book status of LUMAKRAS, and how many listed patents constrain entry?

Featured snippet answer: The U.S. Orange Book lists LUMAKRAS patents that constrain FDA-approval pathways for generic and other abbreviated applications until patent expiry or successful litigation outcomes.

How to use Orange Book coverage in launch modeling

Enterprises typically:

• identify the “earliest expiry” patent
• identify additional later-expiring patents that extend the “last-to-expire” window
• examine whether patents are drug product, method-of-use, or formulation

---

What patent litigation and Paragraph IV challenges affect LUMAKRAS market outlook?

Featured snippet answer: Litigation determines whether competitors can launch at-risk or are delayed by settlements tied to expiry dates.

What investors and licensors monitor

• first Paragraph IV filing timing (signals probability of challenges)
• preliminary injunction events (signals litigation intensity)
• settlement dates and covenants not to sue (determine effective entry dates)

How litigation changes commercial decisions

Even before launch:

• wholesalers and payers may renegotiate contracts in anticipation of entry
• prescribers may shift if label carve-outs limit interchangeability
• marketing spend can be reallocated ahead of expected revenue inflection

---

How does LUMAKRAS compare with other KRAS G12C inhibitors on market potential?

Featured snippet answer: Market potential depends on real-world persistence, subgroup response depth, and whether the agent is preferred in earlier lines as new data emerges.

Competitive comparison framework used in commercial planning

• breadth of label across tumor types
• evidence strength in clinically important subgroups
• discontinuation rates due to adverse events
• ability to combine with other agents without compromising efficacy

---

What commercial risks exist for LUMAKRAS: sequencing displacement, price compression, and adoption ceilings?

Featured snippet answer: The largest commercial risks are share loss from sequencing displacement and price compression as competitors expand, compounded by ceilings in biomarker testing-to-treatment conversion.

Sequencing displacement risk

• if competitors establish earlier-line superiority
• if guidelines favor combinations where LUMAKRAS is not the backbone
• if the benefit narrative weakens for the real-world mix of patients

Price compression risk

• payer renegotiation after competitor launches
• contract reframing with new efficacy evidence
• market-wide trends in oncology reimbursement

Adoption ceiling risk

• limited geographic testing maturity
• slow conversion in community settings
• persistent bottlenecks in molecular profiling

---

Key Takeaways

• LUMAKRAS market dynamics are driven by KRAS G12C biomarker identification, treatment-line adoption, and payer acceptance more than by broad patient demand.
• The financial trajectory is sensitive to competitive displacement as other KRAS G12C inhibitors and combination approaches move earlier in treatment algorithms.
• Patent and Orange Book coverage constrain generic substitution, so revenue risk is mostly sequencing-and-pricing-driven in the near term rather than generic-driven.
• Ongoing quarterly momentum should be monitored via starts, persistence, payer mix, and guideline-driven sequencing shifts.

---

FAQs

1) When does LUMAKRAS face the first potential legal generic entry date in the U.S.?
The first potential entry date is governed by the earliest Orange Book–listed patent expiry and any litigation or settlement outcomes that affect FDA approval timing.

2) Does LUMAKRAS face biosimilar-like substitution risk?
No. LUMAKRAS is a small-molecule therapy; the substitution risk is generic entry under the Hatch-Waxman framework, not biosimilar pathways.

3) How do method-of-use and formulation patents affect generic launch timing?
They can prevent FDA approval or require carve-outs, delaying launch until infringement risk is resolved or patents expire.

4) What real-world metrics best predict LUMAKRAS revenue growth?
KRAS G12C testing-to-treatment conversion (new starts), patient persistence, and payer contract net price over time.

5) What events most often change LUMAKRAS forecast assumptions?
Readouts that alter sequencing (earlier-line adoption or combination preference), competitive data releases, and any settlement or litigation events tied to patent expiry.

---

References

(No sources were provided in the prompt, and no drug- or Orange-Book-specific citations can be produced without external data.)

DrugChatter Q&A for LUMAKRAS

Lumakras supplier from india?
Lumakras mechanism of action?
Buy lumakras tablets from india?
Is lumakras more effective than krazati?